Medicinova (MNOV) Long-Term Investments (2011 - 2022)

Medicinova (MNOV) posted quarterly Long-Term Investments of $10.0 million for Q3 2022, up 1525.19% quarter-over-quarter from $616657.0 in Q1 2018.

Medicinova (MNOV) Long-Term Investments (2011 - 2022) Analysis & Trends

Medicinova (MNOV) has reported Long-Term Investments for 9 consecutive years, with $10.0 million the latest figure, recorded in Q3 2022.

In Q3 2022, Long-Term Investments changed N/A year-over-year to $10.0 million; the TTM figure through Sep 2022 stood at $10.0 million (changed N/A YoY), while the FY2017 annual figure was $616657.0, changed 0.27% from the prior year.
Long-Term Investments improved to $10.0 million in Q3 2022 per MNOV's latest filing, from $616657.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $10.0 million in Q3 2022 and bottomed at $616657.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	Medicinova	68.42 Mn	68.42 Mn	317,759.00	-

Download Data